Sydney Morning Herald, April 27, 2016 – 12:01AM
An emergency contraceptive that works up to five days after unprotected sex has been launched by Australia’s sole supplier of medical abortion drug RU486.
The EllaOne pill, from non-profit pharmaceutical group MS Health, is available from Wednesday.
Read more here
Open Access Journal of Contraception, 19 April 2016 Volume 2016:7 Pages 69—76 Arne Reimers, Department of Clinical Pharmacology, St Olavs University Hospital, and Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway Abstract: Approximately 50% of all pregnancies in women with epilepsy (WWE)...
Hi SASHA readers,
Some people have pointed out that the link in the previous post “Depo-Provera Linked to Increased HIV Risk in Africa” goes to a login page which locks them out. I found the article through google, and it turns out you can only access it in you go in that way, i.e. via google results. I was not aware of this when i posted it.
Cheers,
SASHA
Medscape, January 09, 2015
The injectable contraceptive depot medroxyprogesterone (Depo-Provera or DMPA) is associated with elevated risk for HIV infection among women in low-income or middle-income countries of sub-Saharan Africa, according to a study.
The mechanism behind a link between DMPA and HIV infection is not known.
Read more here
NHS, Monday January 12 2015
“Contraceptive injections moderately increase a woman’s risk of becoming infected with HIV,” The Guardian reports.
The headline was prompted by an analysis of 12 studies, but these results do not prove the injection directly increases the risk of HIV.
Read more here
2014 Guidance statement
WHO, July 2014
The World Health Organization is issuing its contraceptive eligibility guidance for women at high risk of HIV and women living with HIV, in advance of the entire guideline revision. It is anticipated that the revised fifth edition of the MEC will be completed in 2015.
Download the guidelines here